FDA approves upadacitinib for non-radiographic axial spondyloarthritis
October 22, 2022
In response to FDA approval of upadacitinib for the treatment of non-radiographic axial spondylarthritis, Atul Deodhar, M.D., says "Today's FDA approval offers an important new therapeutic option for patients and their caregivers to help take control of their symptoms and disease."